Customizing Clinical Trials for Stakeholder Success Part 2: Measuring Endpoints and Maximizing Impact
In part two of this topic, Donovan Quill, Bob Gilkin, and Andy Szczotka, discuss critical endpoint measurements—primary, secondary, and surrogate markers—and the challenges manufacturers face in addressing unmet medical needs. They explore the balance of safety and effectiveness, the economic benefits of innovative therapies, and the impact of disappointing trial results. This conversation highlights how finding the right partner to help facilitate the successful design and development of clinical trials plays a pivotal role in ensuring payer, clinical and patient needs are comprehensively managed, enhancing patient access to life-saving treatments.
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.